Literature DB >> 29693240

Comparative study of β-catenin and CD44 immunoexpression in oral lichen planus and squamous cell carcinoma.

Massoumeh Zargaran1, Fahimeh Baghaei2, Abbas Moghimbeigi3.   

Abstract

BACKGROUND: Dysfunction of adhesion molecules is believed to play an early and important role in developing cancer. Accordingly, this study aims to compare beta-catenin (β-catenin) and CD44 expression in oral lichen planus (OLP) as a condition with malignant potential and oral squamous cell carcinoma (OSCC).
METHODS: β-Catenin and CD44 expression were evaluated in 15 patients with epithelial hyperplasia (group A), 20 OLP (group B), and 20 OSCC (group C) by immunohistochemistry.
RESULTS: Quantitative and semi-quantitative evaluations revealed β-catenin, and CD44 membranous expression had significant differences among the three groups. Expression of these markers in the OSCC group decreased significantly compared to that of the OLP. Also, nuclear/cytoplasmic expression of β-catenin was significantly different among the three groups, considering that nuclear expression was not observed in any of the epithelial hyperplasia and OLP samples.
CONCLUSIONS: According to the findings of this study, β-catenin and CD44 can differentiate between behavior of OLP and OSCC, while the precancerous nature of OLP and malignant transformation potential of it are not suggested.
© 2018 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29693240     DOI: 10.1111/ijd.14007

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  4 in total

Review 1.  Literature review of cancer stem cells in oral lichen planus: a premalignant lesion.

Authors:  Mahdieh-Sadat Moosavi; Fatemeh Tavakol
Journal:  Stem Cell Investig       Date:  2021-12-30

2.  Alternation of β-catenin and CD44s Immunoexpression in Different Histopathological Grades of Oral Squamous Cell Carcinoma.

Authors:  Massoumeh Zargaran
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

Review 3.  CD44 as a tumor biomarker and therapeutic target.

Authors:  Hanxiao Xu; Mengke Niu; Xun Yuan; Kongming Wu; Aiguo Liu
Journal:  Exp Hematol Oncol       Date:  2020-12-10

4.  CD44 Sorted Cells Have an Augmented Potential for Proliferation, Epithelial-Mesenchymal Transition, Stemness, and a Predominantly Inflammatory Cytokine and Angiogenic Secretome.

Authors:  Shankargouda Patil
Journal:  Curr Issues Mol Biol       Date:  2021-06-21       Impact factor: 2.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.